Talib Dosani, MD
Assistant Professor
Research & Publications
Biography
News
Coauthors
Selected Publications
- Supportive Care for Patients With Myelodysplastic SyndromesStempel J, Podoltsev N, Dosani T. Supportive Care for Patients With Myelodysplastic Syndromes. The Cancer Journal 2023, 29: 168-178. PMID: 37195773, DOI: 10.1097/ppo.0000000000000661.
- A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA ConnecticutXiang J, Dosani T, Hauser R, Cosentino D, Merchant N, Rose M. A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut. Blood 2022, 140: 7864-7865. DOI: 10.1182/blood-2022-168044.
- Impact of Hematology Electronic Consultations on Utilization of Referrals and Patient Outcomes in an Integrated Health Care SystemDosani T, Xiang J, Wang K, Deng Y, Connell NT, Connery D, Levin F, Roy A, Wadia RJ, Wong EY, Rose MG. Impact of Hematology Electronic Consultations on Utilization of Referrals and Patient Outcomes in an Integrated Health Care System. JCO Oncology Practice 2021, 18: e564-e573. PMID: 34914541, DOI: 10.1200/op.21.00420.
- Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer CenterDosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.
- Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affectedDosani T, Covut F, Pinto R, Kim BG, Ali N, Beck R, Maitta R, Downes K, Fox R, Reese J, de Lima M, Malek E. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leukemia & Lymphoma 2019, 60: 2199-2206. PMID: 30845862, DOI: 10.1080/10428194.2019.1573367.
- Host-related immunodeficiency in the development of multiple myelomaDosani T, Mailankody S, Korde N, Manasanch E, Bhutani M, Tageja N, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O. Host-related immunodeficiency in the development of multiple myeloma. Leukemia & Lymphoma 2017, 59: 1127-1132. PMID: 28792255, PMCID: PMC6750254, DOI: 10.1080/10428194.2017.1361026.
- Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myelomaDosani T, Covut F, Beck R, Driscoll J, de Lima M, Malek E. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer Journal 2017, 7: e579-e579. PMID: 28665418, PMCID: PMC5520407, DOI: 10.1038/bcj.2017.60.
- 194 Impact of Lenalidomide on Hematopoietic Myeloid and Erythroid Progenitors: Peripheral Stem Cell Collection May Not be AffectedCovut F, Pinto R, Dosani T, Friedman J, Driscoll J, Downes K, Maitta R, de Lima M, Malek E, Jurdi N. 194 Impact of Lenalidomide on Hematopoietic Myeloid and Erythroid Progenitors: Peripheral Stem Cell Collection May Not be Affected. Transplantation And Cellular Therapy 2017, 23: s190-s191. DOI: 10.1016/j.bbmt.2016.12.301.
- Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple MyelomaMalek E, Dosani T, Pinto R, Covut F, Akabane H, Driscoll J, De Lima M. Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma. Blood 2016, 128: 1862. DOI: 10.1182/blood.v128.22.1862.1862.
- Impact of cytogenetics on myeloma immune microenvironment as reflected by the absolute lymphocyte/monocyte ratio.Dosani T, Akabane H, De Lima M, Driscoll J, Malek E. Impact of cytogenetics on myeloma immune microenvironment as reflected by the absolute lymphocyte/monocyte ratio. Journal Of Clinical Oncology 2016, 34: e23109-e23109. DOI: 10.1200/jco.2016.34.15_suppl.e23109.
- Erratum: The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapiesDosani T, Carlsten M, Maric I, Landgren O. Erratum: The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer Journal 2015, 5: e321-e321. PMID: 26140429, PMCID: PMC4526775, DOI: 10.1038/bcj.2015.49.
- The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapiesDosani T, Carlsten M, Maric I, Landgren O. The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer Journal 2015, 5: e306-e306. PMID: 25885426, PMCID: PMC4450330, DOI: 10.1038/bcj.2015.32.
- Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma PatientsKorde N, Dosani T, Simakova O, Mailankody S, Costello R, Roschewski M, Yuan C, Stetler-Stevenson M, Figg W, Landgren O, Maric I. Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients. Blood 2014, 124: 2080. DOI: 10.1182/blood.v124.21.2080.2080.
- Large granular lymphocyte (LGL) subsets in smoldering multiple myeloma (SMM): Immunophenotypic profiles that predict progression to multiple myeloma (MM).Dosani T, Korde N, Manasanch E, Bhutani M, Tageja N, Mailankody S, Roschewski M, Kwok M, Kazandjian D, Landgren O, Maric I. Large granular lymphocyte (LGL) subsets in smoldering multiple myeloma (SMM): Immunophenotypic profiles that predict progression to multiple myeloma (MM). Journal Of Clinical Oncology 2014, 32: 8597-8597. DOI: 10.1200/jco.2014.32.15_suppl.8597.